These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 6761288

  • 21. [Therapy of obesity using appetite depressants].
    Ikeda Y.
    Nihon Naika Gakkai Zasshi; 1995 Aug 10; 84(8):1290-4. PubMed ID: 7594950
    [No Abstract] [Full Text] [Related]

  • 22. [Mazindol, an anorectic of a new series, in the treatment of obesity (author's transl)].
    Dolecek R.
    Cas Lek Cesk; 1975 Feb 21; 114(8):249-54. PubMed ID: 1095197
    [No Abstract] [Full Text] [Related]

  • 23. Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity.
    Greenway F, Herber D, Raum W, Herber D, Morales S.
    Obes Res; 1999 Jul 21; 7(4):370-8. PubMed ID: 10440593
    [Abstract] [Full Text] [Related]

  • 24. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan 21; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 25. [Therapy of obesity. The initial and continued effectiveness of tenuate in intermittent therapy of moderately and severely obese patients. Double-blind study].
    Albach E, Gianoli AC.
    Fortschr Med; 1977 Sep 08; 95(33):2040-4. PubMed ID: 334650
    [No Abstract] [Full Text] [Related]

  • 26. AN 448 Sandoz (Mazindol) in the treatment of obesity.
    Wallace AG.
    Med J Aust; 1976 Mar 13; 1(11):343-5. PubMed ID: 775265
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A comparative trial of fenfluramine and diethylpropion inbesity.
    Silverstone JT, Cooper RM, Begg RR.
    Br J Clin Pract; 1970 Oct 13; 24(10):423-5. PubMed ID: 4923926
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Pharmaceutical cost savings of treating obesity with weight loss medications.
    Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR.
    Obes Res; 1999 Nov 13; 7(6):523-31. PubMed ID: 10574509
    [Abstract] [Full Text] [Related]

  • 37. The current status of antiobesity drugs.
    Galloway SM, Farquhar DL, Munro JF.
    Postgrad Med J; 1984 Nov 13; 60 Suppl 3():19-26. PubMed ID: 6393107
    [Abstract] [Full Text] [Related]

  • 38. Clinical aspects of the treatment of obesity by drugs: a review.
    Munro JF.
    Int J Obes; 1979 Nov 13; 3(2):171-80. PubMed ID: 393645
    [Abstract] [Full Text] [Related]

  • 39. Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients.
    Slama G, Selmi A, Hautecouverture M, Tchobroutsky G.
    Diabete Metab; 1978 Sep 13; 4(3):193-9. PubMed ID: 361463
    [Abstract] [Full Text] [Related]

  • 40. A double-blind trial of mazindol using a very low calorie formula diet.
    Baird IM, Howard AN.
    Int J Obes; 1977 Sep 13; 1(3):271-8. PubMed ID: 363631
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.